London Research & Pharmaceuticals presents the advancement of LRP-661, their oral cannabidiol sulphate drug candidate at the prestigious Epilepsy Therapies & Diagnostics Development (ETDD) XVII conference in Miami
Globe Newswire15-04-2024, 19:00
Colliers joins the World Green Building Council’s Net Zero Carbon Buildings Commitment 7-12-2023, 19:15